186 related articles for article (PubMed ID: 25853654)
1. Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.
Aparicio-Burgos JE; Zepeda-Escobar JA; de Oca-Jimenez RM; Estrada-Franco JG; Barbabosa-Pliego A; Ochoa-García L; Alejandre-Aguilar R; Rivas N; Peñuelas-Rivas G; Val-Arreola M; Gupta S; Salazar-García F; Garg NJ; Vázquez-Chagoyán JC
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003625. PubMed ID: 25853654
[TBL] [Abstract][Full Text] [Related]
2. Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.
Aparicio-Burgos JE; Ochoa-García L; Zepeda-Escobar JA; Gupta S; Dhiman M; Martínez JS; de Oca-Jiménez RM; Val Arreola M; Barbabosa-Pliego A; Vázquez-Chagoyán JC; Garg NJ
PLoS Negl Trop Dis; 2011; 5(5):e1050. PubMed ID: 21625470
[TBL] [Abstract][Full Text] [Related]
3. TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
Hegazy-Hassan W; Zepeda-Escobar JA; Ochoa-García L; Contreras-Ortíz JME; Tenorio-Borroto E; Barbabosa-Pliego A; Aparicio-Burgos JE; Oros-Pantoja R; Rivas-Santiago B; Díaz-Albiter H; Garg NJ; Vázquez-Chagoyán JC
Vaccine; 2019 Jan; 37(2):248-257. PubMed ID: 30497833
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice.
Gupta S; Garg NJ
PLoS Negl Trop Dis; 2010 Aug; 4(8):e797. PubMed ID: 20706586
[TBL] [Abstract][Full Text] [Related]
5.
Gupta S; Salgado-Jiménez B; Lokugamage N; Vázquez-Chagoyán JC; Garg NJ
Front Immunol; 2019; 10():1456. PubMed ID: 31293599
[No Abstract] [Full Text] [Related]
6. Preventive and therapeutic DNA vaccination partially protect dogs against an infectious challenge with Trypanosoma cruzi.
Quijano-Hernández IA; Castro-Barcena A; Vázquez-Chagoyán JC; Bolio-González ME; Ortega-López J; Dumonteil E
Vaccine; 2013 Apr; 31(18):2246-52. PubMed ID: 23499599
[TBL] [Abstract][Full Text] [Related]
7. Antigenicity and diagnostic potential of vaccine candidates in human Chagas disease.
Gupta S; Wan X; Zago MP; Sellers VC; Silva TS; Assiah D; Dhiman M; Nuñez S; Petersen JR; Vázquez-Chagoyán JC; Estrada-Franco JG; Garg NJ
PLoS Negl Trop Dis; 2013; 7(1):e2018. PubMed ID: 23350012
[TBL] [Abstract][Full Text] [Related]
8. Delivery of antigenic candidates by a DNA/MVA heterologous approach elicits effector CD8(+)T cell mediated immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
Vaccine; 2012 Nov; 30(50):7179-86. PubMed ID: 23079191
[TBL] [Abstract][Full Text] [Related]
9. Specific humoral and cellular immunity induced by Trypanosoma cruzi DNA immunization in a canine model.
Arce-Fonseca M; Ballinas-Verdugo MA; Zenteno ER; Suárez-Flores D; Carrillo-Sánchez SC; Alejandre-Aguilar R; Rosales-Encina JL; Reyes PA; Rodríguez-Morales O
Vet Res; 2013 Mar; 44(1):15. PubMed ID: 23497041
[TBL] [Abstract][Full Text] [Related]
10. Experimental Chagas disease in Balb/c mice previously vaccinated with T. rangeli. II. The innate immune response shows immunological memory: reality or fiction?
Basso B; Marini V
Immunobiology; 2015 Mar; 220(3):428-36. PubMed ID: 25454810
[TBL] [Abstract][Full Text] [Related]
11. Previously unrecognized vaccine candidates control Trypanosoma cruzi infection and immunopathology in mice.
Bhatia V; Garg NJ
Clin Vaccine Immunol; 2008 Aug; 15(8):1158-64. PubMed ID: 18550728
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of dogs with Trypanosoma rangeli induces antibodies against Trypanosoma cruzi in a rural area of Córdoba, Argentina.
Basso B; Marini V; Gauna D; Frias M
Mem Inst Oswaldo Cruz; 2016 Apr; 111(4):271-4. PubMed ID: 27074257
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with Trypanosoma rangeli reduces the infectiousness of dogs experimentally infected with Trypanosoma cruzi.
Basso B; Castro I; Introini V; Gil P; Truyens C; Moretti E
Vaccine; 2007 May; 25(19):3855-8. PubMed ID: 17349724
[TBL] [Abstract][Full Text] [Related]
14. DNA Vaccine Treatment in Dogs Experimentally Infected with
Arce-Fonseca M; Carbajal-Hernández AC; Lozano-Camacho M; Carrillo-Sánchez SDC; Roldán FJ; Aranda-Fraustro A; Rosales-Encina JL; Rodríguez-Morales O
J Immunol Res; 2020; 2020():9794575. PubMed ID: 32455143
[TBL] [Abstract][Full Text] [Related]
15. Cruzipain and Its Physiological Inhibitor, Chagasin, as a DNA-Based Therapeutic Vaccine Against
Cerny N; Bivona AE; Sanchez Alberti A; Trinitario SN; Morales C; Cardoso Landaburu A; Cazorla SI; Malchiodi EL
Front Immunol; 2020; 11():565142. PubMed ID: 33162979
[TBL] [Abstract][Full Text] [Related]
16. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
[TBL] [Abstract][Full Text] [Related]
17. A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.
Gupta S; Garg NJ
PLoS Pathog; 2015 May; 11(5):e1004828. PubMed ID: 25951312
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruzi.
Eickhoff CS; Vasconcelos JR; Sullivan NL; Blazevic A; Bruna-Romero O; Rodrigues MM; Hoft DF
PLoS Negl Trop Dis; 2011 Mar; 5(3):e983. PubMed ID: 21408124
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of cruzipain and GM-CSF DNAs, a new immunotherapeutic vaccine against Trypanosoma cruzi infection.
Cerny N; Sánchez Alberti A; Bivona AE; De Marzi MC; Frank FM; Cazorla SI; Malchiodi EL
Hum Vaccin Immunother; 2016; 12(2):438-50. PubMed ID: 26312947
[TBL] [Abstract][Full Text] [Related]
20. Serum-mediated activation of macrophages reflects TcVac2 vaccine efficacy against Chagas disease.
Gupta S; Silva TS; Osizugbo JE; Tucker L; Spratt HM; Garg NJ
Infect Immun; 2014 Apr; 82(4):1382-9. PubMed ID: 24421046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
